Chemotherapy and Targeted Therapy

The Psychedelic Paradox: Are We Overhyping the Next Wave of Antidepressants? the-psychedelic-paradox-are-we-overhyping-the-next-wave-of-antidepressants

The Psychedelic Paradox: Are We Overhyping the Next Wave of Antidepressants?

Iffa Jayyana August 2, 2026

For years, the narrative surrounding psychedelic medicine has been one of revolutionary promise. From the corridors of...

Navigating the Future of Biomanufacturing: Maja Herold Pedersen on AI, Autonomy, and the CDMO Evolution navigating-the-future-of-biomanufacturing-maja-herold-pedersen-on-ai-autonomy-and-the-cdmo-evolution

Navigating the Future of Biomanufacturing: Maja Herold Pedersen on AI, Autonomy, and the CDMO Evolution

Azzam Bilal Chamdy August 2, 2026

The global biopharmaceutical landscape is undergoing a period of unprecedented capital intensity and structural evolution. At the...

Pharma Weekly Roundup: Strategic Realignment, Clinical Milestones, and IPO Momentum pharma-weekly-roundup-strategic-realignment-clinical-milestones-and-ipo-momentum

Pharma Weekly Roundup: Strategic Realignment, Clinical Milestones, and IPO Momentum

Layla Zulfa August 1, 2026

The global biopharmaceutical sector witnessed a flurry of high-stakes maneuvering this week as industry leaders recalibrated their...

Inflammatory Setback: Novo Nordisk’s Ziltivekimab Failure Sends Shockwaves Through Cardiovascular Biotech inflammatory-setback-novo-nordisks-ziltivekimab-failure-sends-shockwaves-through-cardiovascular-biotech

Inflammatory Setback: Novo Nordisk’s Ziltivekimab Failure Sends Shockwaves Through Cardiovascular Biotech

Raul Delapena Setiawan August 1, 2026

By Jonathan Gardner Published July 31, 2026 The landscape of cardiovascular medicine faced a significant recalibration this...

From Pens to Pills: The Scientific Paradigm Shift in GLP-1 Drug Development Orforglipron molecule. Oral GLP-1 receptor agonist investigated for type 2 diabetes and obesity treatment. Skeletal chemical formula. Paper packaging for drugs. Vector illustration

Orforglipron molecule. Oral GLP-1 receptor agonist investigated for type 2 diabetes and obesity treatment. Skeletal chemical formula. Paper packaging for drugs. Vector illustration

From Pens to Pills: The Scientific Paradigm Shift in GLP-1 Drug Development

Iffa Jayyana July 31, 2026

The pharmaceutical landscape for metabolic disease has undergone a seismic shift. Since the 2017 emergence of semaglutide...

Lilly’s $3.8 Billion Bet: Entering the Frontier of Psychedelic Medicine with AtaiBeckley lillys-3-8-billion-bet-entering-the-frontier-of-psychedelic-medicine-with-ataibeckley

Lilly’s $3.8 Billion Bet: Entering the Frontier of Psychedelic Medicine with AtaiBeckley

Evan Lee Salim July 31, 2026

In a watershed moment for the pharmaceutical industry, Eli Lilly has announced a definitive agreement to acquire...

Market Turbulence: Alnylam Pharmaceuticals Faces Investor Skepticism Following Revenue Miss and Guidance Cut market-turbulence-alnylam-pharmaceuticals-faces-investor-skepticism-following-revenue-miss-and-guidance-cut

Market Turbulence: Alnylam Pharmaceuticals Faces Investor Skepticism Following Revenue Miss and Guidance Cut

Dwi Wanna July 31, 2026

By BioPharma Dive Reporting Team Published July 30, 2026 Alnylam Pharmaceuticals, the pioneer of RNA interference (RNAi)...

The Gold Standard of Nuance: Why Statistical Matching is Redefining Real-World Evidence the-gold-standard-of-nuance-why-statistical-matching-is-redefining-real-world-evidence

The Gold Standard of Nuance: Why Statistical Matching is Redefining Real-World Evidence

Ammar Sabilarrohman July 31, 2026

In the high-stakes world of clinical medicine, the difference between a groundbreaking discovery and a statistical mirage...

Telehealth Under Fire: Hims & Hers Faces Federal Lawsuit Over Privacy and Billing Practices telehealth-under-fire-hims-hers-faces-federal-lawsuit-over-privacy-and-billing-practices

Telehealth Under Fire: Hims & Hers Faces Federal Lawsuit Over Privacy and Billing Practices

Evan Lee Salim July 30, 2026

The landscape of direct-to-consumer (DTC) telehealth is facing a significant reckoning as federal regulators turn their sights...

Ending the "Wait-and-See" Era: The Evolution of Hepatitis C Treatment and the New Frontier for Maviret ending-the-wait-and-see-era-the-evolution-of-hepatitis-c-treatment-and-the-new-frontier-for-maviret

Ending the "Wait-and-See" Era: The Evolution of Hepatitis C Treatment and the New Frontier for Maviret

Iffa Jayyana July 30, 2026

The global landscape of viral hepatitis is undergoing a tectonic shift. For decades, the clinical management of...

Chemotherapy and Targeted Therapy

The Psychedelic Paradox: Are We Overhyping the Next Wave of Antidepressants?

Navigating the Future of Biomanufacturing: Maja Herold Pedersen on AI, Autonomy, and the CDMO Evolution

Pharma Weekly Roundup: Strategic Realignment, Clinical Milestones, and IPO Momentum

Inflammatory Setback: Novo Nordisk’s Ziltivekimab Failure Sends Shockwaves Through Cardiovascular Biotech

From Pens to Pills: The Scientific Paradigm Shift in GLP-1 Drug Development

Lilly’s $3.8 Billion Bet: Entering the Frontier of Psychedelic Medicine with AtaiBeckley

Market Turbulence: Alnylam Pharmaceuticals Faces Investor Skepticism Following Revenue Miss and Guidance Cut

The Gold Standard of Nuance: Why Statistical Matching is Redefining Real-World Evidence

Telehealth Under Fire: Hims & Hers Faces Federal Lawsuit Over Privacy and Billing Practices

Ending the "Wait-and-See" Era: The Evolution of Hepatitis C Treatment and the New Frontier for Maviret

You may have missed

Beyond the Diagnosis: The Psychological and Spiritual Evolution of a Cancer Survivor

Beyond the AI Hype: Why Verseon Is Betting on Physics-First Drug Discovery

The High-Stakes Duel: Novo Nordisk and Eli Lilly Navigate a Volatile Obesity Drug Market

The Viral Stretch: Deconstructing the 103-Million-View Yoga Phenomenon